WASHINGTON – Still haunted by the deaths caused by contaminated heparin that made it into the U.S. drug supply a few years ago and the fact that no one has been held accountable, several senators are calling for drug safety to be elevated to a national security level while creating a level playing field for U.S. drugmakers. Read More
OPKO Health Inc., of Miami, has been authorized to transfer its listing of common stock from the NYSE Amex to the NYSE. It will continue to trade under its current ticker symbol, OPK. The change will be effective Sept. 16. Read More
Oxigene Inc., of South San Francisco, presented a retrospective comparative analysis suggesting Zybrestat (fosbretabulin) confers a one-year survival benefit in patients with anaplastic thyroid cancer (ATC) compared to treatment with chemotherapy alone. The data were collected from five Phase I and Phase II trials and from the Mayo Clinic's database. Read More
Set to make idiopathic pulmonary fibrosis drug Esbriet (pirfenidone) available to patients in Germany Thursday, about six months after receiving European approval, InterMune Inc. is bolstering its cash position via two public offerings totaling $231 million. Read More
Privately held SARcode Bioscience Inc. has enrolled the first patient in OPUS-1, its pivotal Phase III trial of topical SAR 1118 ophthalmic solution. OPUS-1 will study the safety and efficacy of SAR 1118 in the treatment of dry eye. Read More